Other than fighting the Ebola virus, studies have shown that the experimental vaccine could also benefit the patients by protecting them from weight loss.
During the announcement, Inovio said that on successful completion of the early-stage study the partnership will look for another partner to take the development forward.
Drug and vaccine companies have been under pressure to develop Ebola vaccines and conduct clinical trials since the latest, and worst, Ebola outbreak in West Africa that began a few months ago. It’s estimated that up to 20,000 people will be infected in the region my November.
Other companies working on Ebola vaccines are GlaxoSmithKline Plc and NewLink Genetics Corp, while other potential treatments in development are ZMapp by Mapp Biopharmaceutical Inc and AVI 7537 by Sarepta Therapeutics Inc. Last week Canadian based Tekmira Pharmaceuticals Corp announced that its experimental Ebola treatment got authorised by both U.S. and Canadian health regulators for use in patients.